RxDoctor Payments Data

Errol McKenzie, MD

Family Medicine · Fayetteville, NYNPI 1679533624

Payments from drug & device makers

$515in general payments, 2019–2025

Across 22 payments — averaging $23.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$219
  • AstraZeneca$105
  • AbbVie$48
  • Astellas Pharma US Inc$46
  • Pfizer$33
  • ARS Pharmaceuticals Operations, Inc.$30
  • plus $33 from 2 others

What the payments were for

  • Food & beverage$515100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$515 in reported general payments places this provider in the 55th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$68,874
Medicare patients
199
Services billed
792

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide14$24,514
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$19,216
JardianceEmpagliflozin13$17,880
EliquisApixaban13$10,698
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate33$7,718
SynthroidLevothyroxine Sodium33$2,857
Albuterol Sulfate HfaAlbuterol Sulfate74$2,522
Montelukast Sodium200$1,649
Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort30$1,494
Levothyroxine Sodium90$1,341
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide44$1,044
Ezetimibe23$724
Rosuvastatin Calcium55$647
Fluticasone Propionate86$629
Gabapentin62$530

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$219$19,21625 claims
PfizerEliquis$33$10,69813 claims
AbbVieSynthroid$48$2,85733 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,321 family medicine providers in New York.

Other family medicine in Fayetteville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →